BIAL: Drug APTIOM enters the US pharmaceutical market – Portugal
26 November 2013
The anti-epileptic APTIOM, developed by Portuguese pharmaceutical BIAL, will be available for US patients in 2014. Marketed in Europe since 2009, under the brand ZEBINIX, the drug is the result of 15 years of research and an investment of 300 million euros. “After Europe, it is with great pleasure that we now see our work […]












